Table 4.

Disaggregated deterministic results of brexucabtagene autoleucel vs. BSC.

	Brexucabtagene Autoleucel	Literature-Based Meta-Analysis	Incremental
Median survival (years)	12.71	0.88	11.83
Total undiscounted years	13.22	1.76	11.46
Pre-progression	9.30	1.68	7.63
Post-progression	3.92	0.09	3.83
Total discounted years	11.26	1.70	9.56
Pre-progression	7.95	1.63	6.33
Post-progression	3.31	0.08	3.23
Total discounted QALYs	8.34	1.31	7.03
Pre-progression	6.23	1.27	4.97
Pre-Progression, pre-cure point	1.95	1.11	0.85
Pre-Progression, post-cure point	4.28	0.16	4.12
Post-progression	2.14	0.05	2.09
Adverse events	−0.04	−0.01	−0.03
Total discounted costs	CAD 688,040	CAD 66,108	CAD 621,933
Total treatment-related costs	CAD 589,375	CAD 27,946	CAD 561,429
Total drug acquisition	CAD 533,523	CAD 27,221	CAD 506,302
Total apheresis	CAD 1392	CAD 0	CAD 1392
Total drug administration	CAD 211	CAD 726	CAD −515
Total lymphodepletion chemotherapy	CAD 646	CAD 0	CAD 646
Total bridging therapy	CAD 220	CAD 0	CAD 220
Total hospitalization	CAD 53,383	CAD 0	CAD 3383
Total disease management	CAD 57,739	CAD 2490	CAD 55,249
Pre-progression	CAD 3939	CAD 1225	CAD 2714
Post-progression	CAD 53,800	CAD 1264	CAD 52,535
Other costs	CAD 40,926	CAD 35,671	CAD 5255
End of life care	CAD 29,582	CAD 34,589	CAD −5007
Adverse events	CAD 11,344	CAD 1082	CAD 10,262
		Cost/QALY	CAD 88,503

Abbreviations: BSC, best supportive care; QALYs: quality-adjusted life-years.